KOSDAQBiotech & Pharma322510

Jlk

₩5,160▼ 0.19%2026-10-02 close

Market Cap

₩132.2B

Turnover

₩400M

Volume

90,000 shares

Shares out.

25.7M

PER

—

PBR

3.5×

EPS

-₩587

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

JLK at a Crossroads Ahead of Stroke AI Export Ramp

While domestic non-reimbursed billing and preparations for Japan/US exports advance in parallel, revenue over the most recent four quarters has actually contracted, leaving a gap between the growth narrative and reported results.

1
JLK-DWI has entered non-reimbursed billing, JLK-LVO was designated an innovative medical device, and JLK-CTP received a new-health-technology assessment exemption, adding successive domestic regulatory footholds.
2
FY2025 consolidated revenue rose year-on-year to about KRW 3.34 billion, yet revenue over the latest four quarters (Q3 2025–Q2 2026) contracted to roughly KRW 2.72 billion.
3
In Japan the company has signed with multiple distributors including Creavo, Century Medical, Sanshodo and Takeyama, while in the US it holds six FDA 510(k) clearances as it prepares for overseas revenue.
4
Brokerage forecasts for FY2026 revenue range widely from about KRW 9.2 billion to KRW 13.5 billion, with actual achievement hinging on hospital adoption speed and overseas partner execution.
5
Financial strain has also grown, with the debt ratio rising from 51.3% in 2024 to 79.9% in 2025 and owners' equity declining over the same period.

Business structure

JLK Inc., founded in 2014, was the first AI company in Korea to list via the technology special-listing track, and develops and supplies medical-imaging AI solutions centered on stroke diagnosis.

Its flagship product family, MEDIHUB STROKE, is built on CT and MRI imaging and comprises twelve solutions covering the full stroke pathway from hemorrhage to infarction, which the company markets as the world's most comprehensive commercialized full-cycle stroke AI suite.

Its core product JLK-DWI (infarct diagnosis support) became the first in Korea to enter non-reimbursed billing status, moving into an actual revenue-generating stage, while JLK-LVO (large-vessel occlusion detection) has been designated under the integrated review-and-evaluation system for innovative medical devices and is being pushed into clinical use on a non-reimbursed basis.

More recently, the CT perfusion analysis solution JLK-CTP was designated for a new-health-technology assessment exemption, allowing non-reimbursed pricing with no cap and further diversifying the revenue model.

Regarding the hospital-reference expansion driving domestic sales, Hanyang Securities explained in a January 2026 report that the company had accumulated more than 210 hospital references domestically.

Overseas, the company's expansion is centered on Japan, where it has signed distribution agreements with multiple partners including Creavo Technologies, Century Medical, and Sanshodo.

It has also secured six FDA 510(k) clearances in the US and seven PMDA approvals in Japan, laying a regulatory foundation for overseas markets.

More recently, the company has been pursuing portfolio diversification beyond its single stroke focus through a B2B business built on its medical-imaging-specialized multimodal LLM platform JOOMED, and through TRACEGENT-AD, which extends into degenerative brain disease.

Competitors include Lunit, VUNO, DeepNoid and Coreline Soft, all leading domestic medical-AI companies listed on KOSDAQ.

Earnings trend

Quarterly revenue · Operating profit

₩1.1B-₩2.9B25Q2₩900M-₩2.7B25Q3₩900M-₩4.3B25Q4₩400M-₩3.4B26Q1₩500M-₩3.3B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩3.4B-₩8.6B2022₩2.5B-₩7.1B2023₩1.4B-₩12.7B2024₩3.3B-₩13.2B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩1.1B	-₩2.9B	−272.1%
2025Q3	₩900M	-₩2.7B	−298.9%
2025Q4	₩900M	-₩4.3B	−478.7%
2026Q1	₩400M	-₩3.4B	−814.4%
2026Q2	₩500M	-₩3.3B	−643.5%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩3.4B	-₩8.6B	-₩9B	−252.6%	−54.2%	118.9%
2023	₩2.5B	-₩7.1B	-₩7.3B	−287.2%	−62.4%	182.8%
2024	₩1.4B	-₩12.7B	-₩13.5B	−891.9%	−27.3%	51.3%
2025	₩3.3B	-₩13.2B	-₩13.6B	−395.3%	−32.9%	79.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23

Earnings analysis

FY2025 consolidated revenue reached KRW 3.34 billion, up sharply from KRW 1.43 billion in 2024, though relative to KRW 3.42 billion in 2022 and KRW 2.49 billion in 2023, the absolute scale has not yet meaningfully broken out of its historical range.

Operating loss narrowed from KRW 8.63 billion in 2022 to KRW 7.15 billion in 2023, then widened again to KRW 12.73 billion in 2024 and KRW 13.20 billion in 2025, marking a fourth consecutive year of losses near the double-digit-billion-won level.

Operating margin came in at -252.6% in 2022, -287.2% in 2023, -891.9% in 2024 and -395.3% in 2025, reflecting a cost structure that still carries a heavy fixed-cost burden relative to revenue.

Net loss attributable to owners was KRW 13.61 billion in 2025, similar in scale to KRW 13.45 billion in 2024, and wider than the KRW 7–9 billion range seen in 2022–2023.

On a quarterly basis, the loss actually widened from KRW 1.06 billion revenue and KRW 2.89 billion operating loss in Q2 2025 to KRW 0.90 billion revenue, KRW 4.29 billion operating loss and KRW 5.40 billion net loss in Q4 2025.

Combined revenue over the latest four quarters (Q3 2025–Q2 2026) was KRW 2.72 billion, falling short of the roughly KRW 0.84 billion quarterly average implied by annualizing FY2025 revenue, with Q1 2026 (KRW 0.41 billion) and Q2 2026 (KRW 0.52 billion) marking the lowest points in this window.

Net loss attributable to owners ranged between KRW 2.17 billion and KRW 5.40 billion per quarter over the same period, with the trailing four-quarter total reaching KRW 15.13 billion, indicating that the annualized loss scale has not narrowed.

On the balance sheet, owners' equity rose to KRW 49.31 billion in 2024 following capital raising, but fell to KRW 41.36 billion by the end of 2025 as accumulated losses ate into capital, while the debt ratio climbed back from 51.3% to 79.9%.

Operating cash flow was negative KRW 7.90 billion in 2022, negative KRW 6.38 billion in 2023, negative KRW 10.94 billion in 2024 and negative KRW 12.34 billion in 2025, showing a persistent cash outflow of roughly KRW 10 billion per year.

Industry analysis

Korea's medical-AI imaging market is structured around competition among multiple KOSDAQ-listed firms besides JLK, including Lunit, VUNO, DeepNoid and Coreline Soft.

The gap in revenue scale is pronounced: according to a December 2025 report, Lunit's consolidated revenue grew from KRW 1.4 billion in 2020 to KRW 54.2 billion in 2024, with cumulative nine-month revenue up 66% year-on-year to KRW 56.7 billion.

The same report noted that overseas sales accounted for 99% of Lunit's revenue as of the third quarter, effectively making overseas markets the growth driver, and that VUNO's revenue likewise grew roughly twentyfold from KRW 1.3 billion in 2020 to KRW 25.9 billion in 2024.

By contrast, the report pointed out that JLK's revenue fell from about KRW 4.5 billion in 2020 to KRW 1.4 billion in 2024 before recovering, and characterized both VUNO and JLK as having comparatively slower growth due to their domestically weighted revenue structures.

More recently, however, all three companies have entered the Japanese market through different partners — Lunit with Fujifilm, VUNO with Sony subsidiary M3, and JLK with OMRON-affiliated DoctorNet — pointing to a shared shift in emphasis toward overseas markets that carry higher reimbursement rates.

The underlying global medical-AI market is projected to grow from $14.5 billion in 2023 to $148.4 billion in 2029, a 48.1% compound annual growth rate, so the market's overall growth potential continues to be assessed favorably.

A revised 2026 American Heart Association/American Stroke Association acute ischemic stroke guideline now includes automated CT-perfusion analysis software as a recommendation for treatment-candidate selection, which is viewed as a favorable factor given JLK's strength in perfusion-imaging analysis.

Outlook

The company's recent business trajectory can be summarized along two axes: expanding domestic non-reimbursed billing and initiating overseas exports. SangSangIn Securities analyst Ha Tae-gi projected in a March 9, 2026 report that FY2026 revenue would rise 179.7% year-on-year to about KRW 9.2 billion.

Hanyang Securities, in a January 13, 2026 report, forecast FY2026 revenue of about KRW 13.0 billion, split into roughly KRW 4.5 billion domestic, KRW 5.0 billion Japan and KRW 3.5 billion US, noting that given a revenue mix concentrated in the second half, a quarterly break-even could be possible.

On the operational front, JLK-CTP was designated for a new-health-technology assessment exemption in June 2026, enabling uncapped non-reimbursed pricing, and in August the company began a multi-center clinical validation study under a Ministry of Health and Welfare/Korea Health Industry Development Institute AX-Sprint program agreement, involving 22 hospitals nationwide and 41 cerebrovascular specialists to gather real-world evidence for new-health-technology and insurance listing.

Overseas, in August the company signed an additional sales agreement with Japanese trading firm Sanshodo, securing a third Japanese distribution partner following Creavo Technologies and Century Medical.

SangSangIn Securities expects US market exports to begin in the fourth quarter of 2026, with revenue growth materializing more fully in 2027, and anticipates Japan distribution revenue to be recognized first.

Building on technology accumulated in stroke, the company is also expanding into new areas: in August 2026, TRACEGENT-AD, targeting degenerative brain diseases such as Alzheimer's, obtained item certification from the Ministry of Food and Drug Safety, with plans for domestic clinical use and future overseas approvals including from the FDA.

The company itself has noted, however, that these plans could vary depending on external factors such as the pace of hospital adoption, the actual execution capability of overseas distributors, and reimbursement/non-reimbursed pricing policy.

Valuation

PER

—

PBR

3.5×

ROE

-38.5%

EPS

-₩587

BPS

₩1,348

Dividend per share

₩0

JLK has continued to post net losses attributable to owners through the latest four quarters, meaning profit-based metrics such as the price-earnings ratio are not calculable for the company.

Instead, the shares trade at a level that carries a meaningful premium to net asset value, suggesting current valuation reflects expectations tied to the future commercialization story of domestic non-reimbursed billing and Japan/US exports rather than past results.

The company currently pays no dividend, showing a capital-allocation pattern typical of an early-growth company that prioritizes R&D and overseas regulatory/distribution build-out over shareholder returns.

The rise in the debt ratio from 51.3% in 2024 to 79.9% in 2025 provides financial context for growing pressure from accumulated losses eroding capital alongside a rising need for external funding.

Ultimately, the current valuation can be seen as simultaneously incorporating two divergent pieces of information: recent quarterly revenue that has actually contracted, and the growth potential that could materialize if overseas exports gain traction.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23

Bull factors

Expanding Domestic Non-Reimbursed Revenue Model

JLK-DWI became the first product in Korea to enter non-reimbursed billing, and JLK-LVO was subsequently designated under the integrated review-and-evaluation system for innovative medical devices, broadening the company's non-reimbursed revenue base.

More recently, JLK-CTP was also designated for a new-health-technology assessment exemption, enabling uncapped, self-determined pricing. This string of regulatory milestones matters because it creates a foundation for multiple products to reach the revenue-generating stage at the same time.

Diversified Japanese Distribution Network

Since 2024, JLK has secured a total of seven medical-device approvals in Japan, and in August it signed a sales agreement with general trading firm Sanshodo, following earlier deals with Creavo Technologies and Century Medical.

JLK's software has also been cited as an actual clinical example in a Japanese neurology society journal, building technical recognition. Access through multiple distribution partners has the structural advantage of reducing dependence on any single channel.

Portfolio Diversification Beyond Stroke

JLK is pursuing B2B business expansion with medical-imaging equipment manufacturers using its imaging-specialized multimodal LLM platform, JOOMED.

In August 2026, TRACEGENT-AD, targeting degenerative brain diseases such as Alzheimer's, obtained item certification from the Ministry of Food and Drug Safety, establishing a new business axis beyond the company's single stroke focus. This can be read as an attempt to reduce revenue dependence on any single disease area or product.

Bear factors

Uncertainty Around the Revenue Recovery Trend

While FY2025 revenue rose sharply year-on-year, the combined revenue over the latest four quarters (Q3 2025–Q2 2026) was about KRW 2.72 billion, below the average implied by dividing FY2025 annual revenue by four quarters.

Q1 2026 (KRW 0.41 billion) and Q2 2026 (KRW 0.52 billion) in particular fell to the lowest points in this window. The gap between brokerage FY2026 revenue targets (roughly KRW 9.2–13.5 billion) and the actual pace of progress bears watching.

Persistent Large-Scale Losses

Operating losses stayed at KRW 12.73 billion in 2024 and KRW 13.20 billion in 2025, a fourth consecutive year in that range, with an operating margin of -395.3% in 2025.

Net loss attributable to owners over the latest four quarters totaled KRW 15.13 billion, showing the loss has not narrowed on an annualized basis either. Operating cash flow has also continued to show an outflow of roughly KRW 10 billion per year.

Intensifying Competition and Overseas Revenue Gap

Lunit posted FY2024 consolidated revenue of KRW 54.2 billion with a 99% overseas revenue share, and VUNO's revenue reportedly grew roughly twentyfold between 2020 and 2024, whereas JLK's revenue over the same period actually declined before recovering only recently.

The domestic market is structured around competition among several listed firms including Lunit, VUNO, DeepNoid and Coreline Soft, leaving JLK with the task of narrowing the overseas revenue-scale gap versus peers that are further ahead.

Risk factors

Regulatory and Reimbursement Policy Risk

A substantial portion of JLK's revenue depends on temporary, self-determined pricing schemes such as non-reimbursed billing and new-health-technology assessment exemptions.

In practice, the final non-reimbursed price for the stroke-type classification solution JBS-01K was set at about one-third of the level initially notified by the Ministry of Health and Welfare, illustrating how regulatory changes or price adjustments can directly affect profitability.

A similar downward adjustment cannot be ruled out during any future transition to formal insurance reimbursement.

Overseas Execution Risk

Japan and US export progress depends heavily on the actual execution capability of distribution partners and on regulatory approval timelines.

SangSangIn Securities expected that even if US exports begin in Q4 2026, revenue growth would not materialize in earnest until 2027, and brokerage FY2026 revenue forecasts vary widely from about KRW 9.2 billion to KRW 13.5 billion. This underscores continued market uncertainty about the timing and scale of overseas revenue.

Capital Structure and Liquidity Risk

Owners' equity fell from KRW 49.31 billion in 2024 to KRW 41.36 billion in 2025, while the debt ratio rose from 51.3% to 79.9%. Operating cash flow has also shown an outflow of roughly KRW 10 billion per year, so if losses continue, the possibility of additional fundraising or equity dilution cannot be ruled out.

What to watch next

September 2026
Check whether JLK-CTP's non-reimbursed billing actually spreads to multiple hospitals and billing begins in practice.
Mid-November 2026 (expected Q3 filing)
Check whether Q3 2026 revenue recovers from the contraction seen in Q1 and Q2, and whether the operating loss narrows.
Q4 2026
Check whether additional Japan PMDA approvals and the start of US exports proceed on schedule, and monitor progress toward brokerage FY2026 revenue targets of roughly KRW 9.2–13.5 billion.
Second half of 2026
Check whether TRACEGENT-AD's domestic clinical adoption expands and whether overseas approval processes, including with the FDA, are initiated.

Overall view

JLK has broadened its revenue-generation foundation in Korea's stroke AI diagnostics field by securing a series of regulatory footholds — non-reimbursed billing, innovative medical device designation, and a new-health-technology assessment exemption.

FY2025 consolidated revenue rose sharply year-on-year to KRW 3.34 billion, but revenue over the latest four quarters (Q3 2025–Q2 2026) actually contracted from the prior window, and net loss attributable to owners remained in the KRW 15 billion range.

The company has signed with three distributors in Japan and secured multiple FDA clearances in the US as it prepares for overseas revenue, and brokerages have offered a wide range of FY2026 revenue forecasts from about KRW 9.2 billion to KRW 13.5 billion.

These forecasts, however, depend on hospital adoption speed and overseas partner execution, so actual outcomes could diverge.

Financially, a rising debt ratio, shrinking owners' equity, and an annual operating cash outflow of roughly KRW 10 billion are occurring simultaneously, warranting attention to funding pressure as well.

Ultimately, assessment of this company depends on how one weighs the growth narrative of domestic non-reimbursed expansion and overseas exports against recent performance data that has not yet translated into improved earnings.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.